Anellovirus Vector Capsid Modification for Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic agents to eukaryotic cells, such as human cells, are limited in efficiency and often trigger unwanted immune or inflammatory responses.
Innovation Solution
Development of synthetic Anelloviridae family vectors, including Anellovirus particles with a proteinaceous exterior encapsulating genetic elements, which can deliver therapeutic agents or effectors into cells without causing significant immune response, by using modified ORF1 molecules and in vitro assembly techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to deliver therapeutic agents to eukaryotic cells, then delivery can be achieved, but efficiency is limited and unwanted immune or inflammatory responses are triggered
Solution Approach 1:
The patent modifies the viral capsid protein parameters by deleting specific structural domains (arginine-rich region, C-terminal domain) and incorporating recombinase recognition sites. These parameter changes in the protein structure enable the vector to achieve efficient gene delivery while minimizing immune activation, directly resolving the contradiction between delivery efficiency and immune response
Solution Approach 2:
The patent extracts and removes specific harmful structural regions from the viral capsid protein, including the arginine-rich region and C-terminal domain, which are associated with immune recognition. By taking out these elements while retaining essential capsid functions, the patent achieves reduced immune response maintained delivery efficiency
2Productivity
If synthetic Anelloviridae family vectors are developed with modified ORF1 molecules, then delivery efficiency improves and immune response decreases, but vector construction complexity increases
Solution Approach 1:
The patent segments the viral capsid protein into functional domains (N-terminal region, P1 domain, P2 domain, C-terminal domain) and selectively modifies or removes specific segments. This segmentation approach allows targeted modification of only the necessary regions to achieve desired properties while maintaining overall vector functionality, managing construction complexity
Solution Approach 2:
The patent creates a universal vector platform using Anelloviridae family vectors that can deliver various therapeutic agents (genes, effectors, proteins) to different cell types. The modified ORF1 molecule serves multiple functions: capsid formation, recombination site recognition, and delivery, reducing the need for separate components and simplifying overall construction
Data Source
AI summary
This invention relates generally to modified anellovirus capsid proteins, anellovectors, anelloVLPs, and compositions and uses thereof.